RSAD2 and Sjogren syndrome: Low‐expression of protein arginine methyltransferase 5 (PRMT5) through inactivation of RSAD2/NF‐κB signaling pathway alleviates the hyperactivity of primary Sjogren's syndrome (pSS) B cells, which may provide theoretical basis and potential therapeutic targets for clinical treatment of pSS.